Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL5999965

CCC(c1ccncc1)c1cc(Cl)cc(Cl)c1.N

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.49
CYP19A1 P11511 1/20 0.41
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
S1PR1 P21453 1/20 0.38
AKT1 P31749 2/20 0.38
ROCK2 O75116 1/20 0.38
RPS6KA5 O75582 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKACA P17612 1/20 0.38
RPS6KB1 P23443 1/20 0.38
MAPK1 P28482 1/20 0.38
AKT2 P31751 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
PRKX P51817 1/20 0.38
NEK4 P51957 1/20 0.38
PRKCD Q05655 1/20 0.38
PRKG2 Q13237 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL5999692 0.85 CYP19A1 (0.59) CYP17A1CYP19A1SLC6A2SLC6A4SLC6A3
Ammonia Solution, Strong SCHEMBL6000280 0.85 CYP17A1 (0.51) CYP17A1CYP19A1SLC6A2SLC6A4SLC6A3
SCHEMBL377276 0.82 CYP17A1 (0.63) CYP17A1CYP19A1SLC6A2SLC6A4SLC6A3
SCHEMBL28224679 0.82 TSHR (0.42) MAPTCYP3A4LMNA
SCHEMBL17071845 0.81 LMNA (0.48) ALDH1A1MAPTCYP3A4CYP2C19LMNA
SCHEMBL16770738 0.81 LMNA (0.48) ALDH1A1MAPTCYP3A4CYP2C19LMNA
Ammonia Solution, Strong SCHEMBL5999989 0.80 CYP19A1 (0.46) CYP19A1SLC6A2SLC6A4SLC6A3CTSA
Ammonia Solution, Strong SCHEMBL5999595 0.79 SLC6A4 (0.50) CYP17A1CYP19A1SLC6A2SLC6A4SLC6A3
Ammonia Solution, Strong SCHEMBL5999712 0.79 SLC6A3 (0.59) CYP17A1SLC6A2SLC6A4SLC6A3S1PR1
Ammonia Solution, Strong SCHEMBL5999961 0.79 CYP17A1 (0.54) CYP17A1SLC6A2SLC6A4SLC6A3S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CYP17A1 4384/4885CYP19A1 4624/4885SLC6A2 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.